Strengthening endemic country capacity to advance new treatments
Conducting clinical trials on neglected diseases means that research must often be conducted in some of the most remote areas of the world, where there is little infrastructure of any kind, let alone health infrastructure. In some areas, there can also be a risk of political instability. While carrying out clinical research at international standards of quality in such conditions is possible, it requires considerable effort to ensure adequate infrastructure, well trained staff, as well as specialized ethics committees, and well-functioning regulatory authorities are in place.
Maintaining and building R&D regional platforms
As an integral part of DNDi’s model, R&D regional research platforms form part of a broader, positive trend of research networks to maximize worldwide collaborations. The objective is to bring together key regional actors (ministries of health, national control programmes, regulatory authorities, academia, civil society groups, pharmaceutical companies, clinicians and health professionals) to share different experiences, knowledge, and problem-solving techniques.
Leishmaniasis East Africa Platform (LEAP) on leishmaniasis
HAT Platform on sleeping sickness, or human African trypanosomiasis
Chagas Clinical Research Platform (CCRP) on Chagas disease
redeLEISH Network on leishmaniasis
Building health infrastructure, creating R&D training spaces, and setting up research facilities in clinical trial sites
The physical upgrading of facilities needed for clinical research (such as patient wards and diagnostics laboratories) is undertaken by DNDi at trial sites to ensure they are compliant with Good Clinical Practice (GCP) international standards and remain the property of the local public health provider.
Trained staff are needed to carry out GCP compliant trials. Training is important not just at the start of a trial, but is a continuous process which involves upgrading existing skill-sets and training new staff members. From external consultants to experienced trial site staff, the sharing of better practice principles helps to motivate teams working in difficult field conditions.
In 2018, 565 people were trained across the Filarial network, the CCRP, LEAP, and HAT platforms.
DNDi is beginning to better monitor gender representation among researchers and clinicians trained, to ensure equity. In 2018, 259 trainees were women and 306 were men across all programmes.
Transferring technology to local manufacturers
For DNDi, the transfer of technology consists of transferring the industrial development know-how to partners in disease endemic regions to ensure a wide-spread distribution of treatments. It involves providing the required regulatory files and information needed to maintain competitive prices and reinforce the technological and scientific capacities of disease-endemic countries. More information